The landmark US approval of Vertex’s non-opioid pain drug Journavx last week could open up the market for other companies with new therapies without addictive potential. One of these, Algiax Pharmaceuticals, has just unveiled promising Phase IIa results in post-surgical neuropathic pain patients for its candidate, AP-325, which the German company has designed to have no dependency issues.
AP-325 is a novel non-opioid small-molecule therapy that modulates the a GABA-A receptor. However, in contrast with existing GABA-targeting pain drugs such as pregabalin, AP-325 does not penetrate the brain
Key Takeaways
- Vertex's Journavx could help open up a new non-opioid treatment field, and Algiax is targeting neuropathic pain with AP-325